Compare Recursion Pharmaceuticals Inc (RXRX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Verizon Communications Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Verizon Communications Inc trades at $49.79 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 112.6× Recursion Pharmaceuticals Inc's market cap, and Verizon Communications Inc pays a 5.61% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VZ | |
|---|---|---|
Market Cap | $1.86B | $209.44B |
Sector | Health | Media |
52-Week High | $6.79 | $51.38 |
52-Week Low | $2.84 | $38.40 |
Enterprise Value | $1.38B | $396.15B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and strong fundamental metrics including a 15.63% ROE and 11.64% net margin. Recent earnings beats and a 5%+ dividend yield support investor confidence, while the stock trades below the consensus price target of $49.69. The company's fiber expansion deal with Corning and focus on broadband growth provide positive momentum.
Outlook remains positive with cost discipline and shareholder returns driving value, though high debt levels and competitive pressures pose risks. The stock offers income appeal with growth potential from AI infrastructure investments, but requires monitoring of execution on turnaround initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
